UltraCharge obtains evolutionary LIB Cathode IP

Published 09-OCT-2017 12:54 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Battery technology company, UltraCharge Limited (ASX:UTR) this morning announced that it has successfully acquired new cathode intellectual property from Israeli company, ETV Energy Limited.

The new IP assets will complement UTR’s existing lithium ion battery technology which replaces graphite in anodes (negative pole) with a nanotube gel material made from titanium dioxide. This has the potential to revolutionise the market for lithium batteries by producing a battery that is safe, has a longer lifetime and is fast charging.

Its new IP assets will also facilitate new market opportunities, including power bikes and aviation solutions, which have been valued between US$100-500 million each.

UltraCharge possesses the ability to offer a full lithium ion battery solution, combining the company’s fast charging, long life span anode with the new cathode IP asset.

Ultracharge battery

ETV Energy’s high voltage LiMnNo cathode offers greater voltage, energy capacity and power capacity than commercial offerings, and can be produced for just half the cost.

It should be noted that UTR is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.

UltraCharge CEO Kobi Ben-Shabat said, “We are very excited about the additional market opportunities made available to UltraCharge by the inclusion of this high voltage cathode to the company’s battery IP portfolio.

“The acquisition of the new IP asset allows UltraCharge to add experienced battery engineers to our great team, which will further expedite the commercialisation of our patented anode technology with a full battery solution.”

UltraCharge will finalise the conditional acquisition for US$200,000 and up to 90 million shares, which are subject to specific milestones.

The company is anticipating revenues from the acquisition within the next 18-24 months.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free